Trial Profile

Phase II study of DS-6051 in USA

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 01 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Taletrectinib (Primary)
Indications Solid tumours
Focus Therapeutic Use

Most Recent Events

10 Apr 2024 According to a Nuvation Bio media release, AnHeart Therapeutics has been acquired by Nuvation Bio and AnHeart is now a wholly-owned subsidiary of Nuvation Bio.
03 Oct 2019 New trial record
25 Sep 2019 According to a Baoyuan Biopharmaceuticals Technology media releases, trial is expected to start in early 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com